Latest Secondary Hyperparathyroidism (SHPT) News
Parathyroid gland volume more than halved in patients treated with cinacalcet for 8 years.
Using cinacalcet in combination with other therapies may be even more efficacious, according to results from a new review.
Findings from a small study suggest that patients on peritoneal dialysis who have hungry bone syndrome respond better to treatment than those on hemodialysis.
Study supports the hypothesis that altered tubular phosphate handling drives the increase in serum phosphate during SGLT2 inhibition.
In a study, having the single nucleotide polymorphism rs11063112 in fibroblast growth factor 23 was associated with a 32% greater risk for cardiovascular mortality.
In a study of hemodialysis patients, vitamin D users had a lower mortality rate than nonusers: 9 vs 13 per 100 person-years.
Younger age, longer dialysis vintage, and black race are associated with greater cinacalcet prescribing in the United States.
Hyperkalemia developed in nearly 67% of hemodialysis patients during or immediately following total parathyroidectomy with autotransplantation for secondary hyperparathyroidism.
In a small study, more than half of pediatric patients receiving cinacalcet experienced a 30% or greater decline in mean intact parathyroid hormone.
Patients who underwent subtotal vs total parathyroidectomy had half the risk for cardiovascular events.
In a small study of hemodialysis patients with secondary hyperparathyroidism, abdominal aortic calcification decreased more in patients who underwent parathyroidectomy than in those in a control group over 1 year.
Trial results do not support use of vitamin D receptor activators to prevent cardiovascular events in patients with end-stage renal disease and low intact parathyroid hormone levels.
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels.
In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- Study Supports Once-Daily Plazomicin Use for Complicated UTIs
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer